Literature DB >> 35231421

Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer.

Maxime Meylan1, Florent Petitprez2, Etienne Becht3, Antoine Bougoüin1, Guilhem Pupier1, Anne Calvez1, Ilenia Giglioli1, Virginie Verkarre4, Guillaume Lacroix1, Johanna Verneau1, Chen-Ming Sun1, Pierre Laurent-Puig5, Yann-Alexandre Vano6, Reza Elaïdi7, Arnaud Méjean8, Rafaël Sanchez-Salas9, Eric Barret9, Xavier Cathelineau9, Stephane Oudard10, Claude-Agnès Reynaud11, Aurélien de Reyniès12, Catherine Sautès-Fridman1, Wolf Herman Fridman13.   

Abstract

The presence of intratumoral tertiary lymphoid structures (TLS) is associated with positive clinical outcomes and responses to immunotherapy in cancer. Here, we used spatial transcriptomics to examine the nature of B cell responses within TLS in renal cell carcinoma (RCC). B cells were enriched in TLS, and therein, we could identify all B cell maturation stages toward plasma cell (PC) formation. B cell repertoire analysis revealed clonal diversification, selection, expansion in TLS, and the presence of fully mature clonotypes at distance. In TLS+ tumors, IgG- and IgA-producing PCs disseminated into the tumor beds along fibroblastic tracks. TLS+ tumors exhibited high frequencies of IgG-producing PCs and IgG-stained and apoptotic malignant cells, suggestive of anti-tumor effector activity. Therapeutic responses and progression-free survival correlated with IgG-stained tumor cells in RCC patients treated with immune checkpoint inhibitors. Thus, intratumoral TLS sustains B cell maturation and antibody production that is associated with response to immunotherapy, potentially via direct anti-tumor effects.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  B cell maturation; B cell repertoire; Visium; anti-tumor IgG; fibroblasts; plasma cells; renal cell cancer; response to immune check point inhibition; spatial transcriptomics; tertiary lymphoid structures; tumor microenvironment

Mesh:

Substances:

Year:  2022        PMID: 35231421     DOI: 10.1016/j.immuni.2022.02.001

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  12 in total

Review 1.  The emerging landscape of spatial profiling technologies.

Authors:  Jeffrey R Moffitt; Emma Lundberg; Holger Heyn
Journal:  Nat Rev Genet       Date:  2022-07-20       Impact factor: 59.581

2.  STING-induced regulatory B cells compromise NK function in cancer immunity.

Authors:  Sirui Li; Bhalchandra Mirlekar; Brandon M Johnson; W June Brickey; John A Wrobel; Na Yang; Dingka Song; Sarah Entwistle; Xianming Tan; Meng Deng; Ya Cui; Wei Li; Benjamin G Vincent; Michael Gale; Yuliya Pylayeva-Gupta; Jenny P-Y Ting
Journal:  Nature       Date:  2022-10-05       Impact factor: 69.504

Review 3.  Spatial determinants of CD8+ T cell differentiation in cancer.

Authors:  Katherine A Tooley; Giulia Escobar; Ana C Anderson
Journal:  Trends Cancer       Date:  2022-05-05

Review 4.  B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome.

Authors:  Wolf H Fridman; Maxime Meylan; Florent Petitprez; Cheng-Ming Sun; Antoine Italiano; Catherine Sautès-Fridman
Journal:  Nat Rev Clin Oncol       Date:  2022-04-01       Impact factor: 65.011

5.  Localization of T cell clonotypes using the Visium spatial transcriptomics platform.

Authors:  William H Hudson; Lisa J Sudmeier
Journal:  STAR Protoc       Date:  2022-06-10

6.  Anti-tumour antibody-producing plasma cells disseminate from tertiary lymphoid structures.

Authors:  Ellen F Carney
Journal:  Nat Rev Nephrol       Date:  2022-05       Impact factor: 28.314

Review 7.  Emerging concepts regarding pro- and anti tumor properties of B cells in tumor immunity.

Authors:  You Qin; Furong Lu; Kexing Lyu; Alfred E Chang; Qiao Li
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

8.  Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer.

Authors:  Siqi Chen; Ping Xie; Matthew Cowan; Hao Huang; Horacio Cardenas; Russell Keathley; Edward J Tanner; Gini F Fleming; John W Moroney; Alok Pant; Azza M Akasha; Ramana V Davuluri; Masha Kocherginsky; Bin Zhang; Daniela Matei
Journal:  J Clin Invest       Date:  2022-07-15       Impact factor: 19.456

Review 9.  Multiplexed In Situ Spatial Protein Profiling in the Pursuit of Precision Immuno-Oncology for Patients with Breast Cancer.

Authors:  Davide Massa; Anna Tosi; Antonio Rosato; Valentina Guarneri; Maria Vittoria Dieci
Journal:  Cancers (Basel)       Date:  2022-10-06       Impact factor: 6.575

10.  A transcriptional metastatic signature predicts survival in clear cell renal cell carcinoma.

Authors:  Adele M Alchahin; Shenglin Mei; Philip J Saylor; David B Sykes; Peter V Kharchenko; Ninib Baryawno; Ioanna Tsea; Taghreed Hirz; Youmna Kfoury; Douglas Dahl; Chin-Lee Wu; Alexander O Subtelny; Shulin Wu; David T Scadden; John H Shin
Journal:  Nat Commun       Date:  2022-09-30       Impact factor: 17.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.